Overview
New Horizons in Migraine Prevention: Pathways to Personalized Care with CGRPs—the Year in Review
Live Streaming Satellite Symposium!
Registration is closed for this activity.
Join an expert faculty panel as they discuss incorporating anti-CGRP monoclonal antibodies into daily clinical practice for migraine prevention. The 90-minute live streaming satellite symposium will integrate didactic presentation, the patient experience, and expert review of clinical evidence, guideline recommendations, special considerations, and real-world use.
This activity is intended for neurologists, headache specialists, pain specialists, NPs, PAs, and other HCPs who treat patients with migraine disorder.
Migraines represent a common, debilitating disorder that continues to be both undertreated and underdiagnosed. Ninety-five percent of chronic migraine patients do not receive appropriate diagnosis or care, and the few that do, suffer from poor long-term treatment adherence. Calcitonin gene-related peptide (CGRP) monoclonal antibodies are an emerging preventative migraine therapy class that offer benefits over traditional systemic prophylaxis. This activity will review best practices for incorporating CGRP mAbs into daily clinical practice.
Upon completion of this activity, participants will be able to:
• Develop effective strategies for incorporating CGRP mABs into daily clinical practice
• Formulate comprehensive management plans for migraine patients on preventative treatment
• Review current treatment guidelines and patient eligibility for use of CGRP mABs
Best Practices for Incorporating CGRPs into Migraine Treatment (90 minutes)
I. Newly Approved Therapies for Migraine Prevention—Dr. Ailani
II. Expert Recommendations on Use of Anti-CGRP mAbs in Practice—Dr. Newman
III. Special Consideration for Management of CGRP mAbs—Dr. Ailani
IV. Patient Experience—Dr. Dodick
V. Evaluation and Management of Response to Treatment—Faculty Panel
VI. Q&A
I. Newly Approved Therapies for Migraine Prevention—Dr. Ailani
II. Expert Recommendations on Use of Anti-CGRP mAbs in Practice—Dr. Newman
III. Special Consideration for Management of CGRP mAbs—Dr. Ailani
IV. Patient Experience—Dr. Dodick
V. Evaluation and Management of Response to Treatment—Faculty Panel
VI. Q&A
Sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Lundbeck.
Jessica Ailani, MD, FAHS, FAAN (Moderator)
Professor, Neurology
Director, Headache Center
Medstar Georgetown University Hospital
Washington, DC
Professor, Neurology
Director, Headache Center
Medstar Georgetown University Hospital
Washington, DC
David W. Dodick, MD
Professor of Neurology, Department of Neurology
Mayo Clinic College of Medicine
Consultant in Neurology and Program Director, Mayo Clinic Neurology Residency Program
Director, Headache, Sports Neurology, and Concussion Programs
Mayo Clinic
Scottsdale, AZ
Lawrence C. Newman, MD, FAHS, FAAN
Professor, Neurology
NYU Grossman School of Medicine
Director, Headache Division
NYU Langone Health
New York, NY
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
The following financial relationships have been provided:
Jessica Ailani, MD, FAHS, FAAN (Moderator)
Consulting Agreements: Alder, Amgen, Allergan, Biohaven, Eli Lilly and
Company, Impel, Neurodiem, Revance, Satsuma, Theranica, Teva, Zosano
Speakers’ Bureau: Allergan, Amgen, Biohaven, Eli Lilly and Company, Teva
David W. Dodick, MD
Consulting Agreements: Alder Bio Pharmaceuticals Inc.; Allergan; Amgen; Autonomic Technologies; Boston Scientific; Dr. Reddy’s Laboratories Ltd.; Eli Lilly and Company; eNeura, Inc.; INSYS Therapeutics; Teva Pharmaceutical Industries Ltd.; Trigemina, Inc.; Xenon Pharmaceuticals Inc, Zosano
Options: EPIEN Medical, Inc.; Second Opinion, Inc.; Xalan, LLC/GBS Ventures
Patent holder: Allergan PREEMPT injection paradigm
Lawrence C. Newman, MD, FAHS, FAAN
Advisory Board: Allergan, Amgen, Lilly, Supernus, Theranica
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
To receive credit, participants are required to participate in the virtual symposium and complete a posttest and evaluation available at the live streaming link. Certificates will be emailed within two weeks. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse practitioners may participate in this educational activity and earn a certificate of completing as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.
Completion of this activity including the pre, post, and follow-up assessments qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.
